Incidence and cost of hypoglycemia among patients with type 2 diabetes in the United States: Analysis of a health insurance database

Journal of Clinical Outcomes Management

Volumn 18, Issue 10, 2011, Pages 455-462

  Curkendall, Suellen M ^a   Zhang, Bin ^b   Oh, Kelly S ^a   Williams, Setareh A ^c   Pollack, Michael F ^c   Graham, John ^b  

^a THOMSON REUTERS   (United Kingdom)

^b BRISTOL MYERS SQUIBB   (United States)

^c ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; INSULIN; MEGLITINIDE; METFORMIN; PRAMLINTIDE; SULFONYLUREA DERIVATIVE;

ADULT; AGED; ARTICLE; COST OF ILLNESS; EMERGENCY WARD; FEMALE; HEALTH CARE COST; HEALTH INSURANCE; HOSPITAL PATIENT; HUMAN; HYPOGLYCEMIA; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTPATIENT; PATIENT CARE; PRESCRIPTION; UNITED STATES;

EID: 80054932327     PISSN: 10796533     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Miller CD, Phillips LS, Ziemer DC, et al. Hypoglycemia in patients with type 2 diabetes mellitus. Arch Intern Med 2001;161:1653-9. (Pubitemid 32681147)
2. Leese GP, Wang J, Broomhall J, et al. Frequency of severe hypoglycemia requiring emergency treatment in type 1 and 2 diabetes. Diabetes Care 2003;26:1176-80.
3. Fabunmi R, Nielsen LL, Quimbo R, et al. Patient characteristics, drug adherence patterns, and hypoglycemia costs for patients with type 2 diabetes mellitus newly initiated on exenatide or insulin glargine. Curr Med Res Opin 2009;25:777-86.
4. Bullano MF, Fisher MD, Grochulski WD, et al. Hypoglycemic events and glycosylated hemoglobin values in patients with type 2 diabetes mellitus newly initiated on insulin glargine or premixed insulin combination products. Am J Health-Syst Pharm 2006;63:2473-82. (Pubitemid 46391143)
5. Cobden D, Lee WC, Balu S, et al. Health outcomes and economic impact of therapy conversion to a biphasic insulin analog pen among privately insured patients with type 2 diabetes mellitus. Pharmacotherapy 2007;27:948-62. (Pubitemid 46986681)
6. Lee WC, Balu S, Cobden D, et al. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data. Clin Ther 2006;28:1712-25. (Pubitemid 44841979)
7. Heaton A, Martin S, Brelje T. The economic effect of hypoglycemia in a health plan. Manag Care Interface 2003;16:23-7.
8. Lundkvist J, Berne C, Bolinder B, Jönsson L. The economic and quality of life impact of hypoglycemia. Eur J Health Econ 2005;6:197-202.
9. Curkendall SM, Natoli JL, Alexander CM, et al. Economic and clinical impact of inpatient diabetic hypoglycemia. Endocr Pract 2009;15:302-12.
10. Rhoads GG, Orsini LS, Crown W, et al. Contribution of hypoglycemia to medical care expenditures and short-term disability in employees with diabetes. J Occup Environ Med 2005;47:447-52. (Pubitemid 40656778)
11. Brackenridge A, Wallbank H, Lawrenson RA, Russell-Jones D. Emergency management of diabetes and hypoglycaemia. Emerg Med J 2006;23:183-5. (Pubitemid 44295343)
12. Ginde AA, Blanc PG, Lieberman RM, Camargo CA Jr. Validation of ICD-9-CM coding algorithm for improved identification of hypoglycemia visits. BMC Endocr Disord 2008;8:4.
13. Göke B, Gallwitz B, Eriksson J, et al. Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomized controlled trial. Int J Clin Pract 2010;64:1619-31.
14. Phung OJ, Scholle JM, Mehak T, Coleman CI. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA 2010;303:1410-8.